Background. Autoimmune process and immunosuppressive therapy of pemphigus vulgaris would predispose the patients to infections. Aim. We aimed to study the prevalence of infection and pathogenic agents in pemphigus vulgaris patients admitted to dermatology service. Material and methods. This retrospective study was conducted on 155 pemphigus vulgaris patients (68？males, 87？females) admitted to dermatology service between 2009 and 2011. In this study, the diagnosis of pemphigus vulgaris was confirmed by light microscopic and direct immunofluorescence findings. Data were collected through a questionnaire. Results. Of 155？pemphigus vulgaris patients, 33 had infection at admission and 9 acquired nosocomial infection. In addition, 37？cases of oral candidiasis and 15？cases of localized herpes simplex were recorded. Totally, 94？cases of infection were recorded. The occurrence of infection was significantly related to the severity of disease, number of hospital admissions, and presence of diabetes mellitus. The most common pathogenic germs isolated from cultures were Staphylococcus aureus and Escherichia coli. Conclusion. Severity of pemphigus vulgaris and diabetes were directly related with tendency to infections. Staphylococcus aureus and Escherichia coli were the most common pathogenic agents. Due to limitations of retrospective study, a prospective study is recommended. 1. Introduction Pemphigus vulgaris (PV) and pemphigus foliaceus (PF) are organ-specific autoimmune bullous diseases characterized by loss of cell adhesion (acantholysis) and blister formation [1, 2]. These dermatoses are proven to be induced by autoimmune phenomenon [1–3]. Considering this etiology, immunosuppressive therapies are the main treatments available for these disorders. Infections are important complications in these patients attributable to disruption of the epidermal barrier due to the disease itself and immunosuppression induced by treatment [4, 5]. There are many reports regarding predisposition to infections due to immunosuppressive therapy and the immunocompromised state of pemphigus patients [6, 7]. PV has a high prevalence (30 per 100,000 inhabitants) in Iran; in this regard, we have studied this autoimmune disease from many different points of view [8–10]. The aim of the present study was to determine the rate of infection and pathogenic agents in PV patients admitted to dermatology inpatients service through a retrospective study. 2. Material and Methods This retrospective study was performed on 155 PV patients (87 females, 68 males) admitted to the dermatology service of
References
[1]
D. S. Buzina and B. Marinovi？, “From pemphix to desmogleins,” Clinics in Dermatology, vol. 29, no. 4, pp. 355–359, 2011.
[2]
P. R. Cunha and S. R. C. S. Barraviera, “Autoimmune bullous dermatoses,” Anais Brasileiros de Dermatologia, vol. 84, no. 2, pp. 111–122, 2009.
[3]
S. A. Grando, “Pemphigus autoimmunity: hypotheses and realities,” Autoimmunity, vol. 45, no. 1, pp. 7–35, 2012.
[4]
A. Razzaque Ahmed and R. Moy, “Death in pemphigus,” Journal of the American Academy of Dermatology, vol. 7, no. 2, pp. 221–228, 1982.
[5]
T. Piamphongsant and S. Ophaswongse, “Treatment of pemphigus,” International Journal of Dermatology, vol. 30, no. 2, pp. 139–146, 1991.
[6]
F. Z. Belgnaoui, K. Senouci, H. Chraibi et al., “Predisposition to infection in patients with pemphigus. Retrospective study of 141 cases,” Presse Medicale, vol. 36, no. 11, part 1, pp. 1563–1569, 2007.
[7]
M.-J. Ko and C.-Y. Chu, “Disseminated human papillomavirus type 11 infection in a patient with pemphigus vulgaris: confirmed by DNA analysis,” Journal of the American Academy of Dermatology, vol. 51, no. 5, pp. S190–193, 2004.
[8]
C. Chams-Davatchi, M. Valikhani, M. Daneshpazhooh et al., “Pemphigus: analysis of 1209 cases,” International Journal of Dermatology, vol. 44, no. 6, pp. 470–476, 2005.
[9]
C. Chams-Davatchi, “Prevalence and treatment of pemphigus in Iran,” Dermatologic Clinics, vol. 29, no. 4, pp. 681–683, 2011.
[10]
N. Esmaili, Z. Hallaji, R. Abedini, T. Soori, H. Mortazavi, and C. Chams-Davatchi, “Pemphigus vulgaris and herpesviruses: is there any relationship?” International Journal of Dermatology, vol. 49, no. 11, pp. 1261–1265, 2010.
[11]
S. Ikeda, S. Imamura, I. Hashimoto, S. Morioka, M. Sakuma, and H. Ogawa, “History of the establishment and revision of diagnostic criteria, severity index and therapeutic guidelines for pemphigus in Japan,” Archives of Dermatological Research, vol. 295, supplement 1, pp. S12–S16, 2003.
[12]
C. Chams-Davatchi and M. Daneshpazhooh, “Prednisolone dosage in pemphigus vulgaris,” Journal of the American Academy of Dermatology, vol. 53, no. 3, p. 547, 2005.
[13]
S. Beissert, T. Werfel, U. Frieling et al., “A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of bullous pemphigoid,” Archives of Dermatology, vol. 143, no. 12, pp. 1536–1542, 2007.
[14]
M. Hertl and R. Eming, “Autoimmune skin disorders, pemphigus,” in Autoimmune Diseases of the Skin (Pathogenesis, Diagnosis, Management), M. Hertl, Ed., pp. 33–63, Springer, Wien, Austria, 2011.
[15]
A. P. Grammatikos and G. C. Tsokos, “Immunodeficiency and autoimmunity: lessons from systemic lupus erythematosus,” Trends in Molecular Medicine, vol. 18, no. 2, pp. 101–108, 2012.
[16]
T. P. Atkinson, “Immune deficiency and autoimmunity,” Current Opinion in Rheumatology, vol. 24, no. 5, pp. 515–521, 2012.
[17]
S. Ljubojevi？, J. Lipozen？i？, S. Brenner, and D. Budim？i？, “Pemphigus vulgaris: a review of treatment of over a 19-year period,” Journal of the European Academy of Dermatology and Venereology, vol. 16, no. 6, pp. 599–603, 2002.
[18]
O. Mourellou, G. C. Chaidemenos, T. Koussidou, and E. Kapetis, “The treatment of pemphigus vulgaris. Experience with 48 patients seen over an 11-year period,” British Journal of Dermatology, vol. 133, no. 1, pp. 83–87, 1995.
[19]
M. R. Kim, H. C. Kim, and S.-C. Kim, “Long-term prognosis of pemphigus in korea: retrospective analysis of 199 patients,” Dermatology, vol. 223, no. 2, pp. 182–188, 2011.
[20]
N. Chmurova and D. Svecova, “Pemphigus vulgaris: a 11-year review,” Bratislavské Lekárske Listy, vol. 110, no. 8, pp. 500–503, 2009.
[21]
A. J. Kanwar and S. Dhar, “Factors responsible for death in patients with pemphigus,” Journal of Dermatology, vol. 21, no. 9, pp. 655–659, 1994.
[22]
A. R. Brumbaugh and H. L. Mobley, “Preventing urinary tract infection: progress toward an effective Escherichia coli vaccine,” Expert Review of Vaccines, vol. 11, no. 6, pp. 663–676, 2012.
[23]
K. Zouhair, T. El Ouazzani, S. Azzouzi, S. Sqalli, and H. Lakhdar, “Herpes simplex infections in pemphigus: 6 cases,” Annales de Dermatologie et de Venereologie, vol. 126, no. 10, pp. 699–702, 1999.
[24]
A. L. Y. Lecluse and C. A. F. M. Bruijnzeel-Koomen, “Herpes simplex virus infection mimicking bullous disease in an immunocompromised patient,” Case Reports in Dermatology, vol. 2, no. 2, pp. 99–102, 2010.
[25]
E. K. Hale and J.-C. Bystryn, “Laryngeal and nasal involvement in pemphigus vulgaris,” Journal of the American Academy of Dermatology, vol. 44, no. 4, pp. 609–611, 2001.
